GO2 for Lung Cancer is a proud supporter of the recently passed Illinois State Bill (HB 1779), which requires Medicaid as well as state-regulated private insurance plans to cover comprehensive biomarker testing when supported by medical and scientific evidence.

Currently, insurance coverage for biomarker testing is failing to keep pace with innovations and advancements in treatment. There is limited and disparate access to biomarker testing, which is key to connecting lung cancer patients with the most effective treatments. We applaud the bill sponsors, State Representative Mary Flowers  and State Senator Antonio Munoz, for recognizing that not every Illinois community is benefitting from the latest advancements in biomarker testing and precision medicine. Communities that have been marginalized, including communities of color and communities with lower socioeconomic status, are less likely to receive biomarker testing. Those in rural communities and those receiving care in nonacademic medical centers are also less likely to benefit from biomarker testing.

GO2 for Lung Cancer, in partnership with the American Cancer Society Cancer Action Network (ACS CAN) and other health advocacy groups will help to reduce health disparities by working to ensure equitable access to biomarker testing by improving coverage for and access to testing across insurance types nationwide. Additionally, GO2 for Lung Cancer will lead education and awareness of comprehensive biomarker testing among lung cancer patients and providers, as well as policy makers to ensure that patients with lung cancer get the most effective treatment for their cancer. When patients get the right treatment at the right time, it improves survivorship and avoid treatments that will be ineffective or have more adverse effects.

As new ways to understand and treat lung cancer are being established, and comprehensive biomarker testing is approved more quickly, understanding treatment options empowers patients and caregivers. Make sure you are informed by downloading and reading our educational materials. Relevant materials include the Targeted Therapy brochure that explains treatment drugs and why you need testing first, and the Biomarker Testing flyer  that explains what biomarker testing means and how it works.